Results 221 to 230 of about 169,837 (295)
Abstract Heart failure (HF) creates a considerable clinical, humanistic and economic burden on patients and caregivers as well as on healthcare systems. To attenuate the significant burden of HF, there is a need for enhanced management of patients with HF.
Javed Butler +8 more
wiley +1 more source
Chest pain with elevated ST segment in lead V1: a case report. [PDF]
He Z, Pu X, Zeng L.
europepmc +1 more source
Electrocardiogram abnormalities in patients with acne undergoing isotretinoin therapy: a focused review. [PDF]
Islam AW +4 more
europepmc +1 more source
Impact of electrocardiogram monitoring on the frequency of tracheal intubation at birth. [PDF]
de Souza Freire T +3 more
europepmc +1 more source
Cephalalgia-A "Tricky" Symptom for the Cardiologist: Acute Coronary Syndrome Presenting as Headache. [PDF]
Vassiliades A +8 more
europepmc +1 more source
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy +15 more
wiley +1 more source
Arterial pulsation artifact mimicking spiked helmet sign: a case report. [PDF]
Ding H +5 more
europepmc +1 more source
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli +17 more
wiley +1 more source
Role of Valsalva maneuver electrocardiography in the diagnosis of coronary artery disease in senior adults: a prospective cross-sectional study. [PDF]
Zhan Y +5 more
europepmc +1 more source
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies +23 more
wiley +1 more source

